ABSTRACT
INTRODUCTION
First-trimester combined screening based on maternal age (MA), fetal nuchal translucency thickness (NT) and the serum markers free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A provide effective screening for trisomy 21 , with a detection rate of about 90-95% for a false-positive rate (FPR) of 3-5% 1 -3 . However, first-trimester combined screening is also highly effective in the early detection of other chromosomal abnormalities such as trisomies 18 and 13, which are the second and third most common chromosomal defects, respectively 4 . Using the first-trimester algorithm with an adaptation for the specific chromosomal abnormality, the overall detection rate of these three most common abnormalities is about 95% for an overall FPR of 3.1% 5 . Fewer data have been published on triploidy and Turner syndrome. In one prospective screening study, which included 31 triploid pregnancies, the detection rate was 84% for an FPR of 3.1% 6 . Engelbrechtsen et al. 7 examined 30 triploid fetuses and reported a similar detection rate. For Turner syndrome, the detection rate is about 100% for those with hygroma colli but close to 0% for those without an increased NT. The FPR can be further reduced by including an examination of additional ultrasound markers such as anatomy of the nasal bone (NB) and blood flow across the tricuspid valve (TV) and through the ductus venosusassessment of additional ultrasound markers in fetuses with chromosomal abnormalities other than trisomy 21 . In one first-trimester screening study that included approximately 20 000 pregnancies in which these markers in addition to fetal NT were examined, the detection rate in the 64 fetuses with trisomies 18 and 13 and monosomy X was about 95% for an FPR of 2.5% 8 -11 . The utility of screening algorithms for these less common chromosomal abnormalities is often questioned, as it is expected that most cases will be identified by a detailed anomaly scan, which should be part of the first-trimester risk assessment. However, this is not always supported by published data; Sepulveda et al. 12 reviewed their findings in 53 fetuses with trisomy 18 that were examined at 11-13 weeks' gestation. An exomphalos, abnormal positioning of the hands and a cardiac defect were detected in only about 20%, 6% and 4% of cases, respectively. In comparison, fetal NT measurement was above the 99 th centile in about 75% of cases. However, it must be noted that they reported details of cases that were detected between 1997 and 2009. Ultrasound equipment and first-trimester screening have since improved substantially, therefore current data may be closer to those obtained in the second trimester, in which virtually all affected fetuses can be detected by a detailed second-trimester assessment of the anatomy.
In this study, our aim was to examine the performance of first-trimester ultrasound screening for trisomies 18 and 13, triploidy and Turner syndrome based on fetal NT, additional ultrasound markers NB, TV flow and DV flow and a detailed anomaly scan at 11-13 weeks' gestation.
METHODS
This was a retrospective case-matched study involving pregnant women who were seen at the department of prenatal medicine at the University of Tuebingen, Germany, between 2008 and 2014. In our department, an ultrasound examination at 11-13 weeks' gestation always includes the following elements: measurement of crown-rump length (CRL) and NT and a thorough anatomical fetal assessment to look for the presence of major anatomical defects 5, 13, 14 . The additional ultrasound markers NB, TV flow and DV flow are examined in each case.
The NB is considered to be abnormal either if it is not visible or if its echogenicity is the same or lower than that of the skin. Evaluation of blood flow across the TV and through the DV is carried out using pulsed Doppler ultrasound. Abnormal TV flow (tricuspid regurgitation) is diagnosed if it lasts for at least half of systole with a velocity of more than 80 cm/s. DV flow is assessed qualitatively and is considered to be abnormal if the a-wave is reversed. All operators were certified for evaluation of the respective markers by The Fetal Medicine Foundation (FMF), UK, and measurements were performed according to the published guidelines 8 -10 . In each case with a suspected major fetal anomaly, a transabdominal and transvaginal ultrasound examination was repeated by one of two senior consultants (K.O.K., M.H.) and invasive testing was offered. All anomalies reported in this study were confirmed during the course of the pregnancy and after birth. If the pregnancy was terminated and an autopsy was performed, the anomaly was confirmed by a pathologist. In cases in which autopsy was declined, both senior consultants separately re-examined the stored ultrasound images and videoclips. No false-positive cases were found. Minor defects, such as a single umbilical artery or intracardiac echogenic focus, were not included. Accumulation of fluid behind the fetal neck was evaluated in terms of the quantity (i.e. NT) and not its appearance; therefore, the term 'cystic hygroma' was not used. Intrauterine growth restriction was not considered to be a defect.
A search of our digital database (Viewpoint, GE Healthcare, Munich, Germany) was performed to identify all pregnancies with trisomy 18, trisomy 13, triploidy and Turner syndrome that were examined in our department at 11-13 weeks' gestation. These pregnancies were either referred to our department or identified during first-trimester screening. The euploid study population was derived from women who had undergone routine first-trimester screening in our department. Those referred because of abnormal ultrasound or biochemical assessment were not included. For all pregnancies, the absence of a chromosomal defect was confirmed after birth. For each fetus with an abnormal karyotype, 50 randomly selected euploid fetuses were added to the study population.
For all pregnancies, data were collected on MA, gestational age (GA), CRL, fetal NT, additional ultrasound markers NB, TV flow and DV flow, fetal karyotype and all major fetal defects that were found during the early anomaly scan. This information was recorded in a digital database (Microsoft Excel for Mac 11.0, Redmond, WA, USA).
Statistical analysis
In each case, the risk for trisomy was calculated as the summed risk for trisomies 21, 18 and 13. The risk for these trisomies was computed based on first, MA; second, MA and fetal NT; third, MA, NT and one of the additional markers NB, TV flow or DV flow; fourth, MA, NT and all of the additional markers combined; fifth, MA, NT and fetal anomalies; and, finally, on MA, NT and all additional ultrasound markers and fetal anomalies. To compute the risks, the latest algorithms of The FMF, which incorporate DV flow as a dichotomous variable, were used 4,8 -10,15,16 . Detection rates and FPRs were calculated from the proportion of cases with a risk above a given risk threshold. For the last two examined policies, cases with anomalies were classified directly as screen positive and for the further analysis the risk was set at 0.99. Data are given as median (interquartile range) or n (%). NT, nuchal translucency thickness.
RESULTS
The study population consisted of 4641 pregnancies: 4550 euploid and 91 aneuploid fetuses. In the aneuploid group, there were 40 fetuses with trisomy 18, 13 with trisomy 13, 13 with triploidy and 25 with Turner syndrome. Median MA at the time of ultrasound examination was 33.7 (interquartile range (IQR), 30.5-37.0) years, and median GA was 12.6 (IQR, 12.3-13.0) weeks. Maternal and pregnancy characteristics of the study population are provided in Table 1 . The distribution of fetal NT measurements in euploid and aneuploid fetuses is shown in Figure 1 . The median NT was 1.8 mm in euploid fetuses, and 4.8, 6.8, 1.8 and 10.0 mm in fetuses with trisomy 18, trisomy 13, triploidy and Turner syndrome, respectively. NB, TV flow and DV flow were abnormal in 48 (1.1%), 34 (0.7%) and 99 (2.2%) euploid fetuses, respectively. In the aneuploid population, these markers were abnormal in 42 (46.2%), 31 (34.1%) and 62 (68.1%) fetuses, respectively ( Table 1) .
The anomalies detected during the detailed first-trimester ultrasound examination are summarized in Table 2 . At least one defect was found in 60 (1.3%) euploid fetuses and in 33 (82.5%), 13 (100.0%), 11 (84.6%) and 19 (76.0%) cases with trisomy 18, trisomy 13, triploidy and Turner syndrome, respectively. Multiple defects were found in only three (0.1%) euploid fetuses and in 16 (40.0%), 10 (76.9%), seven (53.8%) and three (12.0%) fetuses with trisomy 18, trisomy 13, triploidy and Turner syndrome, respectively. The most common anomalies were cardiac defects, followed by abdominal wall defects and anomalies of the limbs. Tables 3 and 4 summarize the results of different first-trimester screening policies for trisomy 18, trisomy 13, triploidy and Turner syndrome. For an FPR of 3%, the detection rate of screening based on MA and fetal NT was 75.8%. It increased to 84.6-86.8% when adding one of the additional ultrasound markers and was 90.1% if all three markers were examined. If screening was based on MA, fetal NT and a detailed anomaly scan, the detection rate was 94.5%, which increased to 95.6% if the ultrasound markers NB, TV flow and DV flow were also examined. It is noteworthy that, at an FPR of 0.5%, the detection rate of screening based on MA, fetal NT and a detailed anomaly scan is as high as 90.1%. In Figure 2 the receiver-operating characteristics (ROC) curves of these screening policies are shown, which underscore the positive effect of a detailed anomaly scan and examination of the additional ultrasound markers (area under the ROC curve: MA, 0. 
DISCUSSION

Main findings of our study
In this study we have shown that first, in about 1% of euploid fetuses and 75-100% of fetuses with trisomy 18, trisomy 13, triploidy or Turner syndrome, there is at least one major abnormality that can be identified in the first trimester, and second, if screening is based on MA, fetal NT and a detailed fetal anomaly scan, the detection rate of aneuploidy is 95%. The detection rate was about 5% lower if screening was based on MA, fetal NT measurement and all of the additional ultrasound markers (NB, TV flow and DV flow), but without a detailed fetal anomaly scan. The rate was about 10% lower when MA and fetal NT were combined with only one additional ultrasound marker. For evaluating screening performance for a range of chromosomal abnormalities, we used the summed estimated risk for trisomies 21, 18 and 13 using established algorithms, so that an overall FPR of 3% can be considered a realistic target for an adequate detection rate. If an FPR of 0.5% is used, the detection rate is still about 90% if screening is based solely on fetal NT and a detailed anomaly scan. In comparison, such high detection rates with comparatively low FPRs cannot be achieved when screening is based solely on NT measurement and additional ultrasound markers.
Comparison with previous studies
Most published studies have focused on the first-trimester detection rate of certain key anomalies, such holoprosencephaly, exomphalos and megacystis, and examined the prevalence of chromosomal abnormalities in these groups 17 -21 . However, there are fewer published data available regarding the prevalence of structural defects seen in the first trimester in association with various chromosomal abnormalities.
In our first-trimester study population, major defects were found in about 76%, 83%, 85% and 100% of fetuses with Turner syndrome, trisomy 18, triploidy and trisomy 13, respectively. Major defects were found in only 1.3% of the euploid fetuses. This is consistent with the results of a meta-analysis by Syngelaki et al.
14 in which major anomalies were found in 1.6% of 67 779 first-trimester fetuses.
Selpulveda et al. 12 reported in their study that all but one of 53 fetuses with trisomy 18 had a major anomaly in the first trimester. However, they considered increased fetal NT above the 95 th centile and an absent NB to constitute a major anomaly. Wiechec et al. 22 examined 37 cases with trisomy 18 and observed that major anomalies were found in 97% of affected fetuses. They found cardiac defects in about 70% of the cases, while about 30% of the defects were extracardiac 22 . Papageorghiou et al. 23 examined 181 first-trimester fetuses with trisomy 13. They did not perform a full anomaly scan but focused on exomphalos, holoprosencephaly and megacystis. These anomalies were found in 28%, 27% and 12% of cases, respectively. We are not aware of any previous study that focuses on the prevalence of structural defects associated with triploidy and Turner syndrome in the first trimester.
Limitations of our study
The main limitation of our study is that it is retrospective. Furthermore, it should be taken into account that most fetuses with a chromosomal abnormality included in this study were referred to us owing to an abnormal first-trimester screening result or an obvious anomaly. As a result, the prevalence of these findings may be overestimated. This is particularly true of Turner syndrome. However, our results are consistent with those reported in the literature. The results for our euploid population are unaffected, as we used only unselected cases that were seen for routine first-trimester screening.
In addition, we acknowledge that when women opt for termination of pregnancy in the case of a chromosomal abnormality, an autopsy is not routinely performed. In these cases, the reported anomalies were based on an independent review of the respective ultrasound images and videoclips by two fetal-medicine experts.
Implications for clinical practice
Owing to the recent advances in screening based on cell-free DNA (cfDNA), first-trimester ultrasound studies that focus on chromosomal abnormalities are questioned increasingly as the screening performance for trisomy 21 based on cfDNA is inevitably better. However, a detailed anomaly scan prior to cfDNA testing is considered to be mandatory, and if there is a major anomaly or increased NT, cfDNA analysis is not recommended 24 . As it is possible to detect about 95% of fetuses with trisomy 18, trisomy 13, triploidy and Turner syndrome by such a detailed first-trimester ultrasound examination, it could be argued that performing cfDNA testing for these aneuploidies is not necessary and invasive diagnostic testing is the next appropriate step. This approach would result in a reduction in the FPR of the cfDNA analysis; in a recent meta-analysis by Gil et al. 25 , the FPR in cfDNA screening for trisomy 18, trisomy 13 and Turner syndrome was 0.49%, with corresponding detection rates of 96%, 91% and 90%, respectively. We acknowledge that universal application of a detailed first-trimester anomaly scan may be difficult to implement. However, our findings further support the continued utility of first-trimester ultrasound examination even with the availability of cfDNA.
In conclusion, a detailed anomaly scan at 11-13 weeks' gestation can identify about 95% of fetuses with trisomy 18, trisomy 13, triploidy and Turner syndrome.
